Technical Analysis for GILD - Gilead Sciences, Inc.

Grade Last Price % Change Price Change
A 69.24 -0.84% -0.59
GILD closed down 0.84 percent on Wednesday, August 4, 2021, on approximately normal volume.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical GILD trend table...

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
BB Squeeze + Upper Band Touch Range Contraction 0.00%
Upper Bollinger Band Touch Strength 0.00%
Crossed Above 20 DMA Bullish -0.84%
MACD Bullish Signal Line Cross Bullish -0.84%
Expansion Pivot Buy Setup Bullish Swing Setup -0.84%
Bollinger Band Squeeze Range Contraction -0.84%
20 DMA Resistance Bearish 1.30%
MACD Bearish Signal Line Cross Bearish 1.30%
50 DMA Support Bullish 1.30%
Older End-of-Day Signals for GILD ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
10 DMA Support about 16 hours ago
Down 1% about 16 hours ago
Fell Below 10 DMA about 16 hours ago
60 Minute Opening Range Breakdown about 20 hours ago
Expansion Pivot Entry about 21 hours ago
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Gilead Sciences, Inc. Description

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Its products include Stribild, Complera/Eviplera, Atripla, Truvada, Viread, and Emtriva for the treatment of human immunodeficiency virus (HIV) infection in adults; and Viread and Hepsera products for the treatment of liver disease. The company also offers Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension; Ranexa, a tablet used for the treatment of chronic angina; Lexiscan/Rapiscan injection for use as a pharmacologic stress agent in radionuclide myocardial perfusion imaging; Cayston, an inhaled antibiotic for the treatment of respiratory systems in cystic fibrosis patients; and Tamiflu, an oral antiviral capsule for the treatment and prevention of influenza A and B. In addition, it provides other products, such as AmBisome, an antifungal agent to treat serious invasive fungal infections; Vistide, an antiviral injection for the treatment of cytomegalovirus retinitis in patients with AIDS; and Macugen, an anti-angiogenic oligonucleotide to treat neovascular macular degeneration. Further, it has product candidates in various stages for the treatment of cardiovascular diseases, respiratory diseases, and oncology diseases/inflammation. The company markets its products through its commercial teams and/or in conjunction with third-party distributors and corporate partners. Gilead Sciences, Inc. has collaborations with BMS, GSK, Janssen, and Japan Tobacco to develop and commercialize various products. The company was founded in 1987 and is headquartered in Foster City, California.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Major
Keywords: S&P 500 Medicine Biopharmaceutical Nasdaq 100 Diseases Inflammation Hypertension Antibiotic Infection Influenza Macular Degeneration Cardiovascular Disease Coronavirus Pulmonary Arterial Hypertension Cystic Fibrosis Vascular Diseases HIV Organic Chemistry Cardiovascular Diseases Liver Disease Respiratory Disease Immunodeficiency Oligonucleotide Perfusion Respiratory Diseases Hepatotoxins Retinitis Angina Gilead Sciences Prodrugs Fungal Infection Fungal Infections Cytomegalovirus Retinitis Myocardial Perfusion Imaging Oncology Diseases Tenofovir Disoproxil Treatment Of Cardiovascular Disease Treatment Of Life Threatening Diseases

Is GILD a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 70.4
52 Week Low 56.56
Average Volume 6,085,411
200-Day Moving Average 64.46
50-Day Moving Average 67.97
20-Day Moving Average 68.68
10-Day Moving Average 69.10
Average True Range 1.07
ADX 17.44
+DI 28.44
-DI 20.76
Chandelier Exit (Long, 3 ATRs) 67.19
Chandelier Exit (Short, 3 ATRs) 70.58
Upper Bollinger Bands 69.99
Lower Bollinger Band 67.37
Percent B (%b) 0.71
BandWidth 3.80
MACD Line 0.35
MACD Signal Line 0.34
MACD Histogram 0.0132
Fundamentals Value
Market Cap 86.79 Billion
Num Shares 1.25 Billion
EPS 1.01
Price-to-Earnings (P/E) Ratio 68.76
Price-to-Sales 3.24
Price-to-Book 4.28
PEG Ratio 0.43
Dividend 2.72
Dividend Yield 3.93%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 70.68
Resistance 3 (R3) 70.77 70.38 70.44
Resistance 2 (R2) 70.38 70.01 70.34 70.36
Resistance 1 (R1) 69.81 69.79 69.62 69.72 70.28
Pivot Point 69.42 69.42 69.32 69.38 69.42
Support 1 (S1) 68.85 69.05 68.66 68.76 68.20
Support 2 (S2) 68.46 68.83 68.42 68.12
Support 3 (S3) 67.89 68.46 68.04
Support 4 (S4) 67.80